

Keith T Flaherty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4024628/publications.pdf>

Version: 2024-02-01

361
papers

67,282
citations

2975

93
h-index

767

249
g-index

394
all docs

394
docs citations

394
times ranked

58870
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: <i>post hoc</i> analysis from Eastern Cooperative Oncology Groupâ€American College of Radiology Imaging Network (ECOGâ€ACRIN) E2805. <i>BJU International</i> , 2022, 129, 718-722.	2.5	1
2	Oncogenic KIT Induces Replication Stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1413-1424.e6.	0.7	3
3	Randomized Phase III Trial Evaluating Spaltalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600â€Mutant Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1428-1438.	1.6	90
4	Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. <i>Journal of Clinical Oncology</i> , 2022, 40, 1552-1561.	1.6	26
5	Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. <i>JCO Precision Oncology</i> , 2022, 6, e2100424.	3.0	9
6	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. <i>Cell Reports Medicine</i> , 2022, 3, 100500.	6.5	13
7	Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. , 2022, 10, e004036.		24
8	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. <i>British Journal of Dermatology</i> , 2022, 187, 401-410.	1.5	21
9	STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming. <i>Nature Communications</i> , 2022, 13, 1859.	12.8	21
10	A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOGâ€ACRIN Cancer Research Group (EAQ152). <i>Cancer</i> , 2022, 128, 1381-1391.	4.1	11
11	Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas. <i>Clinical Cancer Research</i> , 2022, 28, 2180-2195.	7.0	12
12	Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study. <i>Investigational New Drugs</i> , 2022, 40, 1051-1065.	2.6	4
13	Spaltalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i). , 2022, 10, e004226.		9
14	Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study. <i>Cancer Research</i> , 2022, 82, 6403-6403.	0.9	0
15	Abstract CT160: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol EAY131-Z1L. <i>Cancer Research</i> , 2022, 82, CT160-CT160.	0.9	1
16	HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors. <i>Nature Communications</i> , 2022, 13, .	12.8	23
17	Targeted and immunotherapies in <i>BRAF</i> mutant melanoma: where we stand and what to expect. <i>British Journal of Dermatology</i> , 2021, 185, 253-262.	1.5	20
18	Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administrationâ€™Melanoma Research Alliance Public Workshop. <i>Clinical Cancer Research</i> , 2021, 27, 394-401.	7.0	5

#	ARTICLE	IF	CITATIONS
19	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. <i>Journal of Translational Medicine</i> , 2021, 19, 17.	4.4	6
20	The State of Melanoma: Emergent Challenges and Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 2678-2697.	7.0	53
21	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	54
22	Effect of Capiivasertib in Patients With an <i>AKT1 E17K</i> -Mutated Tumor. <i>JAMA Oncology</i> , 2021, 7, 271.	7.1	49
23	Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. , 2021, 9, e002092.		7
24	Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i> -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i> -Mutated Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2996-3004.	7.0	23
25	Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805). <i>Clinical Cancer Research</i> , 2021, 27, 3397-3403.	7.0	5
26	Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab153.	0.9	20
27	Efficacy and Safety of Trametinib in <i>Non-V600 BRAF</i> Mutant Melanoma: A Phase II Study. <i>Oncologist</i> , 2021, 26, 731-e1498.	3.7	20
28	Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with <i>BRAF V600</i> : Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9560-9560.	1.6	2
29	Evolution of delayed resistance to immunotherapy in a melanoma responder. <i>Nature Medicine</i> , 2021, 27, 985-992.	30.7	67
30	Loss of <i>ACK1</i> Upregulates <i>EGFR</i> and Mediates Resistance to <i>BRAF</i> Inhibition. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1317-1324.e1.	0.7	9
31	Rejection of benign melanocytic nevi by nevus-resident CD4 ⁺ T cells. <i>Science Advances</i> , 2021, 7, .	10.3	6
32	Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective. <i>Cancer Discovery</i> , 2021, 11, 1881-1885.	9.4	19
33	Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2021, 80, 20-31.	1.9	33
34	Quality of life in patients with <i>BRAF</i> -mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021, 152, 116-128.	2.8	7
35	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-“PD-1 Monotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5993-6000.	7.0	70
36	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies <i>LPAR1</i> in Melanoma Progression and Therapy Resistance. <i>Cancer Research</i> , 2021, 81, 5230-5241.	0.9	9

#	ARTICLE	IF	CITATIONS
37	Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. <i>European Journal of Cancer</i> , 2021, 153, 234-241.	2.8	15
38	The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2018-2027.e4.	0.7	8
39	REDCap-Based Operational Tool to Guide Care Coordination in a Multidisciplinary Cutaneous Oncology Clinic. <i>JCO Oncology Practice</i> , 2021, 17, 527-533.	2.9	1
40	A Modified Nucleoside 6-Thio-2-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. <i>Clinical Cancer Research</i> , 2021, 27, 6800-6814.	7.0	10
41	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. <i>Nature Communications</i> , 2021, 12, 6023.	12.8	21
42	Abstract P117: Oncogenic Kit induces replication stress and induces Chk1/ATR inhibitor sensitivity in melanoma. , 2021, , .		0
43	A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 460-467.	4.1	60
44	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600 mutant melanoma. <i>European Journal of Cancer</i> , 2020, 126, 33-44.	2.8	130
45	The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1021-1029.	6.3	138
46	Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 214-222.	1.6	106
47	Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial. <i>JCO Precision Oncology</i> , 2020, 4, 1207-1216.	3.0	6
48	Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). <i>Journal of Clinical Oncology</i> , 2020, 38, 3883-3894.	1.6	168
49	Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. <i>Nature Medicine</i> , 2020, 26, 1557-1563.	30.7	78
50	LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600 mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. <i>Annals of Oncology</i> , 2020, 31, S1172.	1.2	56
51	Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib±cobimetinib: a pooled analysis of four clinical trials. <i>Journal of Translational Medicine</i> , 2020, 18, 294.	4.4	8
52	Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. <i>Science Advances</i> , 2020, 6, .	10.3	37
53	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. <i>Nature Communications</i> , 2020, 11, 3946.	12.8	71
54	Dabrafenib and Trametinib in Patients With Tumors With BRAF ^{V600E} Mutations: Results of the NCI-MATCH Trial Subprotocol H. <i>Journal of Clinical Oncology</i> , 2020, 38, 3895-3904.	1.6	145

#	ARTICLE	IF	CITATIONS
55	SARS-CoV-2 viral load is associated with increased disease severity and mortality. <i>Nature Communications</i> , 2020, 11, 5493.	12.8	702
56	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 6039-6050.	7.0	24
57	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. <i>Journal of Clinical Oncology</i> , 2020, 38, 2407-2417.	1.6	102
58	SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth. <i>Molecular Cancer Research</i> , 2020, 18, 1560-1573.	3.4	13
59	Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. <i>Cancer Discovery</i> , 2020, 10, 1282-1295.	9.4	75
60	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020, 130, 126-138.	2.8	84
61	Tracking early response to immunotherapy. <i>Nature Cancer</i> , 2020, 1, 160-162.	13.2	9
62	Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). <i>Clinical Cancer Research</i> , 2020, 26, 1812-1819.	7.0	47
63	Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2020, 132, 112-121.	2.8	22
64	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 358-372.	10.7	94
65	Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. <i>Journal of Urology</i> , 2020, 203, 684-689.	0.4	22
66	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 10012-10012.	1.6	14
67	Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 6511-6523.	7.0	62
68	Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G ₄ Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2987-2999.	1.6	126
69	Impact of depth of response on survival in patients treated with cobimetinib±vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. <i>British Journal of Cancer</i> , 2019, 121, 522-528.	6.4	20
70	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. <i>Nature Immunology</i> , 2019, 20, 1231-1243.	14.5	217
71	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019, 119, 97-106.	2.8	75
72	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	10.7	155

#	ARTICLE	IF	CITATIONS
73	Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting. <i>Annals of Oncology</i> , 2019, 30, v543-v544.	1.2	2
74	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i> -mutated Melanoma to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2019, 25, 6852-6867.	7.0	74
75	Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation. <i>Clinical Cancer Research</i> , 2019, 25, 7202-7217.	7.0	29
76	Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 109, 61-69.	2.8	63
77	MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in <i>BRAF</i> -, <i>NRAS</i> -, and <i>NF1</i> -Mutant Melanomas. <i>Cancer Discovery</i> , 2019, 9, 526-545.	9.4	73
78	Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. <i>Journal of Clinical Oncology</i> , 2019, 37, 2062-2071.	1.6	80
79	Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation positive metastatic melanoma treated with vemurafenib ± cobimetinib. <i>European Journal of Cancer</i> , 2019, 116, 45-55.	2.8	9
80	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	27.0	909
81	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 897-905.	4.2	38
82	Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. <i>Molecular Systems Biology</i> , 2019, 15, e8323.	7.2	25
83	Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFN γ pathways. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 549-562.	27.6	72
84	Gut microbiota dependent anti-tumor immunity restricts melanoma growth in <i>Rnf5a</i> ^{-/-} mice. <i>Nature Communications</i> , 2019, 10, 1492.	12.8	114
85	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 2699-2707.	7.0	98
86	Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. <i>Oncologist</i> , 2019, 24, 671-679.	3.7	36
87	Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 6098-6106.	7.0	14
88	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. <i>Nature Communications</i> , 2019, 10, 5157.	12.8	46
89	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , 2019, 25, 1916-1927.	30.7	541
90	CMET-33. PHASE II STUDY OF PALBOCICLIB IN BRAIN METASTASES HARBORING CDK PATHWAY ALTERATIONS. <i>Neuro-Oncology</i> , 2019, 21, vi58-vi59.	1.2	0

#	ARTICLE	IF	CITATIONS
91	ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. <i>Cancer Discovery</i> , 2019, 9, 396-415.	9.4	71
92	Response to Immune Checkpoint Antibodies: Not All Responses Are Created Equal. <i>Clinical Cancer Research</i> , 2019, 25, 910-911.	7.0	4
93	A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF ^{high} /AXL ^{low} melanoma. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 280-291.	3.3	31
94	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF ^{V600E} mutant melanoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 9512-9512.	1.6	16
95	Selective uveal melanoma inhibition with calcium channel blockade. <i>International Journal of Oncology</i> , 2019, 55, 1090-1096.	3.3	10
96	Liquid biopsy using plasma proteomic profiling to reveal predictors of immunotherapy response. <i>Journal of Clinical Oncology</i> , 2019, 37, 130-130.	1.6	1
97	Angiogenic factor and cytokine analysis among patients with renal cell carcinoma treated with adjuvant VEGFR TKIs. <i>Journal of Clinical Oncology</i> , 2019, 37, 586-586.	1.6	0
98	Prognostic models for advanced melanoma patients treated with anti-PD-1 monotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 133-133.	1.6	0
99	Organ site-specific radiological responses in anti-PD-1 monotherapy treated advanced melanoma patients. <i>Journal of Clinical Oncology</i> , 2019, 37, 9552-9552.	1.6	0
100	Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	79
101	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2467-2472.	7.1	131
102	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1423172.	4.6	25
103	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. <i>Lancet Oncology</i> , The, 2018, 19, 310-322.	10.7	486
104	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. <i>Cancer Discovery</i> , 2018, 8, 184-195.	9.4	283
105	Mechanisms of resistance to immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 2018, 118, 9-16.	6.4	944
106	Anti-PD-1 antibody treatment for melanoma. <i>Lancet Oncology</i> , The, 2018, 19, e219.	10.7	10
107	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 603-615.	10.7	751
108	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 4771-4784.	7.0	29

#	ARTICLE	IF	CITATIONS
109	A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. <i>Oncologist</i> , 2018, 23, 658-e72.	3.7	47
110	First-in-Human trial of the PI3K β -selective inhibitor SAR260301 in patients with advanced solid tumors. <i>Cancer</i> , 2018, 124, 315-324.	4.1	29
111	Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018, 8, 196-215.	9.4	392
112	Moving treatments earlier to move further forwards. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 75-76.	27.6	7
113	Long-Term Outcomes in Patients With BRAF ^{V600E} Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2018, 36, 667-673.	1.6	196
114	Emerging Strategies in Systemic Therapy for the Treatment of Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 751-758.	3.8	30
115	CMET-16. THE ROLE OF SURGICAL RESECTION OF MELANOMA BRAIN METASTASES IN THE IMMUNOTHERAPY ERA. <i>Neuro-Oncology</i> , 2018, 20, vi56-vi57.	1.2	0
116	Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. <i>Melanoma Research</i> , 2018, 28, 605-610.	1.2	24
117	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , 2018, 175, 984-997.e24.	28.9	892
118	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	28.9	1,260
119	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1315-1327.	10.7	469
120	Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1369-1375.	0.5	36
121	High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. <i>Cancer</i> , 2018, 124, 3706-3714.	4.1	340
122	When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age. <i>Annals of Internal Medicine</i> , 2018, 169, 233.	3.9	20
123	Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF ^{V600E} Mutated Metastatic Melanoma. <i>JAMA Oncology</i> , 2018, 4, 1382.	7.1	65
124	Toward Minimal Residual Disease-Directed Therapy in Melanoma. <i>Cell</i> , 2018, 174, 843-855.e19.	28.9	514
125	Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. <i>Nature Medicine</i> , 2018, 24, 1545-1549.	30.7	473
126	Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. <i>JCI Insight</i> , 2018, 3, .	5.0	107

#	ARTICLE	IF	CITATIONS
127	Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GE) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.. Journal of Clinical Oncology, 2018, 36, 100-100.	1.6	20
128	Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors.. Journal of Clinical Oncology, 2018, 36, 101-101.	1.6	29
129	Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.. Journal of Clinical Oncology, 2018, 36, 2503-2503.	1.6	26
130	Autoimmune genetic variants as germline biomarkers of response in melanoma immunotherapy treatment.. Journal of Clinical Oncology, 2018, 36, 3079-3079.	1.6	2
131	Characterization of immune related hepatitis (irH) from immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2018, 36, 3087-3087.	1.6	2
132	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in <i>BRAF</i>-mutant melanoma.. Journal of Clinical Oncology, 2018, 36, 9504-9504.	1.6	23
133	Immune checkpoint inhibition (ICI) in advanced cutaneous squamous cell carcinoma (cSCC): Clinical response and correlative biomarker analysis.. Journal of Clinical Oncology, 2018, 36, 9564-9564.	1.6	7
134	Adverse events of special interest in the phase 3 COLUMBUS study.. Journal of Clinical Oncology, 2018, 36, 9567-9567.	1.6	3
135	Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC).. Journal of Clinical Oncology, 2018, 36, 447-447.	1.6	11
136	Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget, 2018, 9, 8206-8222.	1.8	54
137	Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade.. Journal of Clinical Oncology, 2018, 36, 3074-3074.	1.6	5
138	Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunotherapy resistance.. Journal of Clinical Oncology, 2018, 36, 9581-9581.	1.6	0
139	Micro<scp>RNA</scp>â€125a promotes resistance to <scp>BRAF</scp> inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell and Melanoma Research, 2017, 30, 328-338.	3.3	34
140	Adjuvant Treatment for High-Risk Clear Cell Renal Cancer. JAMA Oncology, 2017, 3, 1249.	7.1	131
141	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 435-445.	10.7	399
142	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of Oncology, 2017, 28, 1631-1639.	1.2	549
143	Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. Cancer Research, 2017, 77, 2318-2327.	0.9	235
144	Oncogenic RAS Regulates Long Noncoding RNA <i>Orilnc1</i> in Human Cancer. Cancer Research, 2017, 77, 3745-3757.	0.9	34

#	ARTICLE	IF	CITATIONS
145	Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. <i>Clinical Cancer Research</i> , 2017, 23, 4680-4692.	7.0	8
146	An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. <i>Journal of Experimental Medicine</i> , 2017, 214, 1691-1710.	8.5	71
147	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55.	2.8	160
148	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 863-873.	10.7	561
149	Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 463-482.	27.6	945
150	Academic Cancer Center Phase I Program Development. <i>Oncologist</i> , 2017, 22, 369-374.	3.7	0
151	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017, 8, 1136.	12.8	686
152	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. <i>Nature</i> , 2017, 550, 133-136.	27.8	146
153	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 472-492.	329.8	1,662
154	Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017. <i>European Journal of Cancer</i> , 2017, 83, 247-257.	2.8	236
155	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. <i>Nature Communications</i> , 2017, 8, 607.	12.8	109
156	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. <i>Science</i> , 2017, 357, 1156-1160.	12.6	1,059
157	Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. <i>EMBO Molecular Medicine</i> , 2017, 9, 1011-1029.	6.9	63
158	BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 6203-6214.	7.0	36
159	A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. <i>Cancer Medicine</i> , 2017, 6, 1904-1914.	2.8	24
160	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. <i>Annals of Oncology</i> , 2017, 28, 2581-2587.	1.2	201
161	Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. <i>Cell Reports</i> , 2017, 21, 2796-2812.	6.4	77
162	Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. <i>Oncologist</i> , 2017, 22, 1429-e139.	3.7	31

#	ARTICLE	IF	CITATIONS
163	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. <i>Cell Reports</i> , 2017, 21, 1936-1952.	6.4	72
164	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. <i>Cell Reports</i> , 2017, 21, 1953-1967.	6.4	117
165	Tissue-Agnostic Drug Development. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 222-230.	3.8	25
166	Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. <i>Radiographics</i> , 2017, 37, 2132-2144.	3.3	87
167	Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2500-2500.	1.6	11
168	First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2508-2508.	1.6	13
169	Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3057-3057.	1.6	24
170	Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9512-9512.	1.6	6
171	A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9553-9553.	1.6	3
172	Impact of gene expression profiles on clinical predictors of survival in patients (pts) with <i>BRAF</i> ^{V600} -mutated metastatic melanoma (mM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9556-9556.	1.6	6
173	Inflammatory arthritis: An under-recognized immune-relate adverse effect.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14565-e14565.	1.6	1
174	Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results.. <i>Journal of Clinical Oncology</i> , 2017, 35, 370-370.	1.6	5
175	Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. <i>Oncotarget</i> , 2017, 8, 25395-25417.	1.8	64
176	ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14102-e14102.	1.6	0
177	Expression quantitative trait loci (eQTLs) as germline determinants of melanoma immunotherapy response.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3017-3017.	1.6	0
178	In the pipeline: encorafenib and binimetinib in BRAF-mutated melanoma. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 745-747.	0.3	4
179	Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. <i>Cancer Discovery</i> , 2016, 6, 740-753.	9.4	565
180	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. <i>Nature</i> , 2016, 532, 250-254.	27.8	290

#	ARTICLE	IF	CITATIONS
181	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. <i>Science</i> , 2016, 352, 189-196.	12.6	3,421
182	The Conundrum of Genetic “Drivers” in Benign Conditions. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw036.	6.3	113
183	Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 4452-4465.	7.0	112
184	Parallel <i>In Vivo</i> Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities. <i>Clinical Cancer Research</i> , 2016, 22, 6031-6038.	7.0	16
185	Biomarkers in Melanoma: Lessons from Translational Medicine. <i>Trends in Cancer</i> , 2016, 2, 305-312.	7.4	11
186	Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. <i>Nature Medicine</i> , 2016, 22, 1056-1061.	30.7	62
187	The state of melanoma: challenges and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 404-416.	3.3	77
188	High-Throughput Testing of Novel “Novel Combination Therapies for Cancer: An Idea Whose Time Has Come. <i>Cancer Discovery</i> , 2016, 6, 956-962.	9.4	8
189	MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. <i>Clinical Cancer Research</i> , 2016, 22, 6088-6098.	7.0	43
190	PIPELINES: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 713-729.	4.7	27
191	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. <i>Lancet Oncology</i> , The, 2016, 17, 1743-1754.	10.7	266
192	An Open-Label, Dose “Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 5204-5210.	7.0	19
193	Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer. <i>JAMA Ophthalmology</i> , 2016, 134, 855.	2.5	62
194	PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases <i>In Vitro</i> and <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2016, 22, 5818-5828.	7.0	68
195	Overall Survival and Durable Responses in Patients With <i>BRAF</i> V600 “Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 871-878.	1.6	266
196	Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. <i>Cancer Discovery</i> , 2016, 6, 382-399.	9.4	139
197	Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. <i>Cancer Cell</i> , 2016, 29, 270-284.	16.8	198
198	Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1002-1011.	0.7	51

#	ARTICLE	IF	CITATIONS
199	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncimmunology</i> , 2016, 5, e1136044.	4.6	55
200	A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. <i>Cancer Biology and Therapy</i> , 2016, 17, 778-784.	3.4	8
201	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN) Tj ETQq1 1 0.784314 13.7 / Overlock 529	13.7	529
202	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016, 53, 125-134.	2.8	137
203	Correlation of <i>BRAF</i> Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. <i>Clinical Cancer Research</i> , 2016, 22, 567-574.	7.0	185
204	Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 374-382.	7.0	38
205	Association of plasma exosomal mRNA changes with long-term durable response to ipilimumab (IPI) in metastatic melanoma (MM) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3037-3037.	1.6	2
206	Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3502-3502.	1.6	114
207	Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Updated phase 1 results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4117-4117.	1.6	1
208	Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6580-6580.	1.6	60
209	Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in <i>NRAS</i> -mutant cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9500-9500.	1.6	34
210	Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) ± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9536-9536.	1.6	3
211	The impact of obesity on outcomes in metastatic melanoma (MM) patients (pts) treated with dabrafenib and trametinib.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9566-9566.	1.6	1
212	NCI-MATCH (Molecular Analysis for Therapy Choice) â€” a national signal finding trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2606-TPS2606.	1.6	6
213	Discovery and clinical introduction of first-in-class imipridone ONC201. <i>Oncotarget</i> , 2016, 7, 74380-74392.	1.8	111
214	A multivariate analysis of prognostic factors from assure (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 618-618.	1.6	0
215	Functional characterization of non-V600 BRAF mutations and their response to Trametinib (Tram).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9537-9537.	1.6	0
216	Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma. <i>Experimental Dermatology</i> , 2015, 24, 657-658.	2.9	8

#	ARTICLE	IF	CITATIONS
217	Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. <i>Nature Medicine</i> , 2015, 21, 741-750.	30.7	107
218	Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. <i>European Journal of Cancer</i> , 2015, 51, 1435-1443.	2.8	61
219	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 444-451.	13.7	1,175
220	New Strategies in Melanoma: Entering the Era of Combinatorial Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 2424-2435.	7.0	29
221	BMET-04LEPTOMENINGEAL CARCINOMATOSIS IN MELANOMA. <i>Neuro-Oncology</i> , 2015, 17, v45.4-v45.	1.2	0
222	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. <i>Cancer Cell</i> , 2015, 28, 773-784.	16.8	327
223	Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. <i>Cell Reports</i> , 2015, 11, 1458-1473.	6.4	55
224	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. <i>Nature Genetics</i> , 2015, 47, 250-256.	21.4	434
225	EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. <i>Cancer Discovery</i> , 2015, 5, 274-287.	9.4	107
226	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology, The</i> , 2015, 16, 15-17.	10.7	10
227	Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapyâ€“Mediated Metastatic Melanoma Phenotype. <i>Cancer Discovery</i> , 2015, 5, 264-273.	9.4	82
228	Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma. <i>Melanoma Management</i> , 2015, 2, 133-147.	0.5	3
229	Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 491-499.e2.	1.2	14
230	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	2.8	71
231	Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 2892-2897.	7.0	31
232	MITF Modulates Therapeutic Resistance through EGFR Signaling. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1863-1872.	0.7	76
233	When are signal transduction targeted therapies acting as immunotherapy?. <i>Cancer Biology and Therapy</i> , 2015, 16, 645-647.	3.4	1
234	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology, The</i> , 2015, 16, 1389-1398.	10.7	206

#	ARTICLE	IF	CITATIONS
235	Anti-PD-1 therapiesâ€”a new first-line option in advanced melanoma. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 625-626.	27.6	38
236	Precision medicine for cancer with next-generation functional diagnostics. <i>Nature Reviews Cancer</i> , 2015, 15, 747-756.	28.4	466
237	<scp>W</scp>nt5<scp>A</scp> promotes an adaptive, senescentâ€like stress response, while continuing to drive invasion in melanoma cells. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 184-195.	3.3	77
238	Effectively targeting <scp>CRAF</scp>: rational serendipity targeting <scp>SRC</scp>?. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 242-243.	3.3	0
239	The E3 ligase APC/C ^{Cdh1} promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth. <i>Science Signaling</i> , 2015, 8, ra87.	3.6	21
240	Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. <i>Lancet Oncology</i> , The, 2015, 16, e522-e526.	10.7	20
241	BRAF Inhibition Generates a Hostâ€Tumor Niche that Mediates Therapeutic Escape. <i>Journal of Investigative Dermatology</i> , 2015, 135, 3115-3124.	0.7	80
242	Gauging the Long-Term Benefits of Ipilimumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1865-1866.	1.6	41
243	A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. <i>Oncologist</i> , 2015, 20, 617-618.	3.7	9
244	Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. <i>JAMA Oncology</i> , 2015, 1, 1340.	7.1	63
245	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. <i>Cell</i> , 2015, 162, 1242-1256.	28.9	507
246	Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. <i>Clinical Cancer Research</i> , 2015, 21, 5215-5221.	7.0	17
247	Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. <i>New England Journal of Medicine</i> , 2015, 372, 30-39.	27.0	2,240
248	Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 102-102.	1.6	3
249	Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2506-2506.	1.6	10
250	First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).. <i>Journal of Clinical Oncology</i> , 2015, 33, 2564-2564.	1.6	5
251	Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3615-3615.	1.6	17
252	Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4114-4114.	1.6	3

#	ARTICLE	IF	CITATIONS
253	Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4508-4508.	1.6	5
254	Plasma-based monitoring of BRAF mutations during therapy for malignant melanoma (MM) using combined exosomal RNA and cell-free DNA analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9017-9017.	1.6	7
255	Updated overall survival (OS) results for BRF113220, a phase II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 9036-9036.	1.6	12
256	A phase II study of combined therapy with vemurafenib (vem) and high-dose interleukin-2 (aldesleukin); Tj ETQq0 0,0rgBT /Oyerlock 10	1.6	2
257	Profiling exosomal mRNAs in patients undergoing immunotherapy for malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22159-e22159.	1.6	4
258	Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 403-403.	1.6	24
259	Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. <i>PLoS ONE</i> , 2015, 10, e0140310.	2.5	39
260	Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. <i>Oncotarget</i> , 2015, 6, 40535-40556.	1.8	59
261	Detection of low abundant somatic mutations in circulating exosomal RNA and cfDNA with next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11061-11061.	1.6	0
262	Palliative care and hospice use among melanoma patients treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 116-116.	1.6	0
263	New drugs in development for melanoma. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 717-9.	0.3	0
264	The melanoma metastasis X-factor. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 698-698.	3.3	0
265	Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3210-3218.	4.1	21
266	Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer. <i>Cancer Discovery</i> , 2014, 4, 1377-1386.	9.4	76
267	One Hippo and many masters: differential regulation of the Hippo pathway in cancer. <i>Biochemical Society Transactions</i> , 2014, 42, 816-821.	3.4	12
268	Major therapeutic developments and current challenges in advanced melanoma. <i>British Journal of Dermatology</i> , 2014, 170, 36-44.	1.5	20
269	Cutaneous Granulomatous Eruption and Successful Response to Potent Topical Steroids in Patients Undergoing Targeted BRAF Inhibitor Treatment for Metastatic Melanoma. <i>JAMA Dermatology</i> , 2014, 150, 307.	4.1	44
270	The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF±. <i>Cancer Discovery</i> , 2014, 4, 1214-1229.	9.4	174

#	ARTICLE	IF	CITATIONS
271	Systematic identification of signaling pathways with potential to confer anticancer drug resistance. <i>Science Signaling</i> , 2014, 7, ra121.	3.6	163
272	Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2014, 2, 643-654.	3.4	226
273	Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics. <i>PLoS ONE</i> , 2014, 9, e101286.	2.5	42
274	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, 297-304.	10.7	55
275	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With <i>BRAF</i> ^{V600} -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2014, 32, 3697-3704.	1.6	173
276	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	27.0	1,572
277	A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. <i>Cancer Discovery</i> , 2014, 4, 816-827.	9.4	448
278	Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib. <i>Clinical Cancer Research</i> , 2014, 20, 3328-3337.	7.0	33
279	Cyclin-dependent kinases as therapeutic targets in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 351-365.	3.3	21
280	Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2014, 2, 632-642.	3.4	512
281	Isolation and Molecular Characterization of Circulating Melanoma Cells. <i>Cell Reports</i> , 2014, 7, 645-653.	6.4	91
282	Safety and efficacy of vemurafenib in <i>BRAF</i> ^{V600E} and <i>BRAF</i> ^{V600K} mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , The, 2014, 15, 323-332.	10.7	890
283	Commentary: Molecular testing in melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 863-870.	1.2	4
284	Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11061-11061.	1.6	2
285	LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 534-534.	1.6	25
286	Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8026-8026.	1.6	22
287	Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with <i>BRAF</i> ^{V600} mutation-positive (+) metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 9010-9010.	1.6	13
288	COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic <i>BRAF</i> ^{V600E/K} mutation-positive cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 9011-9011.	1.6	40

#	ARTICLE	IF	CITATIONS
289	First-in-human phase I "basket" study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS2629-TPS2629.	1.6	2
290	NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic <i>NRAS</i> -mutant cutaneous melanoma.. Journal of Clinical Oncology, 2014, 32, TPS9102-TPS9102.	1.6	3
291	An Active Learning Approach for Rapid Characterization of Endothelial Cells in Human Tumors. PLoS ONE, 2014, 9, e90495.	2.5	24
292	The effect and mechanism of M402 on gemcitabine uptake into pancreatic tumors.. Journal of Clinical Oncology, 2014, 32, 215-215.	1.6	0
293	Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.. Journal of Clinical Oncology, 2014, 32, TPS9105-TPS9105.	1.6	0
294	microRNA (miRNA) expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy (CP) in metastatic melanoma (MM) treated on the intergroup trial E2603.. Journal of Clinical Oncology, 2014, 32, 9048-9048.	1.6	0
295	Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib.. Journal of Clinical Oncology, 2014, 32, 9062-9062.	1.6	0
296	ONC201, a small molecule Foxo3a activator, activity against patient-derived glioblastoma tumor-initiating cells.. Journal of Clinical Oncology, 2014, 32, e13022-e13022.	1.6	0
297	A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature, 2013, 504, 138-142.	27.8	401
298	BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clinical Cancer Research, 2013, 19, 1225-1231.	7.0	832
299	Resistance to BRAF-targeted therapy in melanoma. European Journal of Cancer, 2013, 49, 1297-1304.	2.8	311
300	BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. Clinical Cancer Research, 2013, 19, 393-403.	7.0	336
301	Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 1767-1774.	1.6	335
302	Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 373-379.	1.6	199
303	A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.. Journal of Clinical Oncology, 2013, 31, 2500-2500.	1.6	100
304	BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM).. Journal of Clinical Oncology, 2013, 31, 9005-9005.	1.6	16
305	Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).. Journal of Clinical Oncology, 2013, 31, 9010-9010.	1.6	118
306	Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition.. Journal of Clinical Oncology, 2013, 31, 9015-9015.	1.6	3

#	ARTICLE	IF	CITATIONS
307	Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9016-9016.	1.6	5
308	Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9020-9020.	1.6	1
309	A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9026-9026.	1.6	6
310	Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9028-9028.	1.6	32
311	Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in <i>BRAF</i> V600-dependent advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9029-9029.	1.6	28
312	Analysis of serum biomarkers and tumor genetic alterations from a phase II study of lenvatinib in patients with advanced BRAF wild-type melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9058-9058.	1.6	2
313	Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9066-9066.	1.6	1
314	A phase I study of the combination of sorafenib (Sor) and bortezomib (Bor) in patients (pts) with metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9076-9076.	1.6	2
315	Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9094-9094.	1.6	7
316	Increase in blood pressure with sorafenib exposure: Renal cell carcinoma (RCC) versus other solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15564-e15564.	1.6	1
317	Medical oncologistsâ€™ clinical experiences and comfort levels with 20 recently approved agents.. <i>Journal of Clinical Oncology</i> , 2013, 31, e17570-e17570.	1.6	1
318	The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20050-e20050.	1.6	2
319	The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 345-345.	1.6	14
320	Increase in blood pressure with sorafenib exposure in renal cell carcinoma versus other solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 384-384.	1.6	0
321	Survival patterns following brain metastases for patients with melanoma in the targeted therapy era.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9064-9064.	1.6	0
322	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. <i>Journal of Clinical Oncology</i> , 2013, 31, 533-533.	1.6	0
323	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. <i>Journal of Clinical Oncology</i> , 2013, 31, 145-145.	1.6	0
324	EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i>-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib. <i>Cancer Discovery</i> , 2012, 2, 227-235.	9.4	852

#	ARTICLE	IF	CITATIONS
325	Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. <i>New England Journal of Medicine</i> , 2012, 367, 1694-1703.	27.0	2,445
326	Survival in BRAF V600 Mutant Advanced Melanoma Treated with Vemurafenib. <i>New England Journal of Medicine</i> , 2012, 366, 707-714.	27.0	1,955
327	Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 841-846.	3.3	14
328	From genes to drugs: targeted strategies for melanoma. <i>Nature Reviews Cancer</i> , 2012, 12, 349-361.	28.4	323
329	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2012, 367, 107-114.	27.0	1,976
330	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. <i>Nature</i> , 2012, 487, 500-504.	27.8	1,561
331	Targeting Metastatic Melanoma. <i>Annual Review of Medicine</i> , 2012, 63, 171-183.	12.2	57
332	M402, a heparan sulfate mimetic and novel candidate for the treatment of pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4056-4056.	1.6	3
333	Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4500-4500.	1.6	6
334	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF ^{V600E} -mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8502-8502.	1.6	86
335	Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAF ^{V600E} melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8503-8503.	1.6	19
336	Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8510-8510.	1.6	41
337	Predicting early relapse in patients with BRAF ^{V600E} melanoma with a highly sensitive blood BRAF assay.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8516-8516.	1.6	2
338	Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8569-8569.	1.6	21
339	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1BA8509-1BA8509.	1.6	14
340	New Options and New Questions: How to Select and Sequence Therapies for Patients with Metastatic Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 524-530.	3.8	3
341	Abstract LB-350: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition by vemurafenib. , 2012, , .		1
342	Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8526-8526.	1.6	0

#	ARTICLE	IF	CITATIONS
343	Association of the activation of the mTOR pathway with prognosis in Chinese melanoma patients.. Journal of Clinical Oncology, 2012, 30, 8561-8561.	1.6	0
344	A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma.. Journal of Clinical Oncology, 2012, 30, 8567-8567.	1.6	0
345	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM).. Journal of Clinical Oncology, 2012, 30, LBA8509-LBA8509.	1.6	13
346	mTOR pathway activation in KIT-mutated melanoma with acquired imatinib resistance.. Journal of Clinical Oncology, 2012, 30, 8562-8562.	1.6	0
347	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine, 2011, 364, 2507-2516.	27.0	6,976
348	Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress. Pigment Cell and Melanoma Research, 2011, 24, 107-109.	3.3	5
349	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 2011, 480, 387-390.	27.8	1,298
350	BRAF Inhibitors and Melanoma. Cancer Journal (Sudbury, Mass), 2011, 17, 505-511.	2.0	28
351	Is It Good or Bad to Find a <i>BRAF</i> Mutation?. Journal of Clinical Oncology, 2011, 29, 1229-1230.	1.6	10
352	New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances. Clinical Cancer Research, 2011, 17, 4922-4928.	7.0	34
353	Mutation-driven drug development in melanoma. Current Opinion in Oncology, 2010, 22, 178-183.	2.4	94
354	Narrative Review: BRAF Opens the Door for Therapeutic Advances in Melanoma. Annals of Internal Medicine, 2010, 153, 587.	3.9	34
355	Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma. Biochemical Pharmacology, 2010, 80, 638-646.	4.4	16
356	BRAF, a target in melanoma. Cancer, 2010, 116, 4902-4913.	4.1	106
357	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467, 596-599.	27.8	1,610
358	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 2010, 468, 968-972.	27.8	1,325
359	Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. New England Journal of Medicine, 2010, 363, 809-819.	27.0	3,288
360	Advances in drug development. BRAF validation in melanoma. Clinical Advances in Hematology and Oncology, 2010, 8, 31-4.	0.3	8

#	ARTICLE	IF	CITATIONS
361	A Prospective Study of Body Mass Index, Hypertension, and Smoking and the Risk of Renal Cell Carcinoma (United States). <i>Cancer Causes and Control</i> , 2005, 16, 1099-1106.	1.8	119